Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ECE1 | P42892 | 1/20 | 0.45 |
| ▸ | MMP1 | P03956 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | ACE | P12821 | 5/20 | 0.43 |
| ▸ | CTSK | P43235 | 3/20 | 0.43 |
| ▸ | CTSL | P07711 | 1/20 | 0.43 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.43 |
| ▸ | MME | P08473 | 1/20 | 0.42 |
| ▸ | CTSB | P07858 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8601030 | 0.86 | ECE1 (0.49) | ECE1MMP1NPC1RAB9ACTSK | |
| SCHEMBL8085479 | 0.81 | FAAH (0.42) | MMP1NPC1RAB9A | |
| SCHEMBL1458342 | 0.81 | ECE1 (0.55) | ECE1NPC1RAB9ACTSKPSMB5 | |
| SCHEMBL10793880 | 0.81 | NPC1 (0.51) | NPC1RAB9A | |
| SCHEMBL10793891 | 0.81 | NPC1 (0.51) | NPC1RAB9A | |
| SCHEMBL8872910 | 0.79 | ECE1 (0.52) | ECE1MMP1NPC1RAB9ACTSK | |
| SCHEMBL8872913 | 0.79 | ECE1 (0.52) | ECE1MMP1NPC1RAB9ACTSK | |
| SCHEMBL10790971 | 0.77 | LTA4H (0.53) | NPC1RAB9A | |
| SCHEMBL6946518 | 0.77 | SLC1A3 (0.49) | MMP1CTSKCTSLPSMB5CTSB | |
| SCHEMBL6946515 | 0.77 | SLC1A3 (0.49) | MMP1CTSKCTSLPSMB5CTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6790834-B1 | Cytostatic agents | BRITISH BIOTECH PHARMACEUTICALS, LTD. (GB) | 2004-09-14 | — | — | US | disclosed |
| EP-1062202-B1 | CYTOSTATIC AGENTS | BRITISH BIOTECH PHARM (GB) | 2003-01-15 | — | — | EP | disclosed |
| US-6462023-B1 | SUCH AS 2-HYDROXY-HYDROXYCARBAMOYL-METHYL)-4-METHYL-PENTANOYLAMINE)-2-PHENYL -ETHANOIC ACID CYCLOPENTYL ESTER; INHIBITING HYPERPROLIFERATIVE TUMOURGENIC CELLS SUCH AS MELANOMA AND/OR LYMPHOMA CELLS | BRITISH BIOTECH PHARMACEUTICALS, LTD. (GB) | 2002-10-08 | — | — | US | disclosed |
| EP-0925278-B1 | CYTOSTATIC HYDROXAMIC ACID DERIVATIVES | BRITISH BIOTECH PHARM (GB) | 2002-07-17 | — | — | EP | disclosed |
| US-6169075-B1 | ANTITUMOR AGENT INHIBITING THE PROLIFERATION OF A RANGE OF RAPIDLY DIVIDING TUMOUR CELLS LIKE MELANOMA AND/OR LYMPHOMA CELLS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 2001-01-02 | — | — | US | disclosed |
| EP-1062202-A1 | CYTOSTATIC AGENTS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 2000-12-27 | — | — | EP | disclosed |
| EP-0835240-B1 | MATRIX METALLOPROTEINASE INHIBITORS | BRITISH BIOTECH PHARM (GB) | 2000-11-02 | — | — | EP | disclosed |
| WO-1999046241-A1 | CYTOSTATIC AGENTS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1999-09-16 | — | — | WO | disclosed |
| EP-0925278-A1 | CYTOSTATIC HYDROXAMIC ACID DERIVATIVES | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1999-06-30 | — | — | EP | disclosed |
| US-5917090-A | INHIBIT TUMOR NECROSIS FACTOR; ANTIARTHRITIC AGENTS | BRITISH BIOTECH PHARMACEUTICALS LTD. (GB) | 1999-06-29 | — | — | US | disclosed |
| EP-0835240-A1 | MATRIX METALLOPROTEINASE INHIBITORS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1998-04-15 | — | — | EP | disclosed |
| WO-1998011063-A1 | CYTOSTATIC HYDROXAMIC ACID DERIVATIVES | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1998-03-19 | — | — | WO | disclosed |
| WO-1997002239-A1 | MATRIX METALLOPROTEINASE INHIBITORS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1997-01-23 | — | — | WO | disclosed |